Literature DB >> 6088039

Constitutive production and release of a lymphokine with macrophage-activating factor activity distinct from gamma-interferon by a human T-cell leukemia virus-positive cell line.

E S Kleinerman, R Zicht, P S Sarin, R C Gallo, I J Fidler.   

Abstract

Culture supernatant fluids from the human T-cell leukemia virus-positive cell line C10/MJ-2 were found to contain a soluble factor with macrophage-activating factor (MAF) activity. The MAF activity of this culture supernatant fluid was stable at 100 degrees for 2 min and was unaffected by treatment with human anti-gamma-interferon (IFN-gamma) monoclonal antibody. Both treatments neutralized greater than 97% IFN-gamma activity from the supernatant fluid as measured by virus neutralization. Furthermore, this MAF activity was not due to contamination with endotoxins since the Limulus amebocyte lysate assay was negative (less than 0.125 ng/ml) and preincubation of the C10/MJ-2 supernatant fluid with polymyxin B did not diminish its activating potential. By contrast, human IFN-gamma rendered human monocytes tumoricidal only when combined with Salmonella typhosa lipopolysaccharide (LPS) at a minimum dose of 0.2 ng/ml. The concentrations of both LPS and IFN-gamma were crucial to achieve activation since IFN-gamma at doses less than 10 units/ml did not activate human monocytes even when combined with maximal doses of LPS (0.5 ng/ml). Finally, when human IFN-gamma admixed with LPS was preincubated with polymyxin B, its activating potential was completely abrogated. Collectively, these data suggest that the human T-cell line C10/MJ-2 constitutively produces a diffusable product distinct from IFN-gamma which activates human monocytes to lyse tumor cells. Thus, this cell line could provide a good source of a unique human MAF for future purification procedures.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088039

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Effect of Nocardia rubra cell wall skeleton on augmentation of cytotoxicity function in human pleural macrophages.

Authors:  M Sakatani; T Ogura; T Masuno; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives.

Authors:  S Sone; G Lopez-Berestein; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Rate and efficiency of complement-dependent phagocytosis in cytolytic and non-cytolytic inflammatory macrophages.

Authors:  A J Norin; R A De Pinho
Journal:  Immunology       Date:  1986-08       Impact factor: 7.397

4.  Murine T-cell clones against Entamoeba histolytica: in vivo and in vitro characterization.

Authors:  M Denis; K Chadee
Journal:  Immunology       Date:  1989-01       Impact factor: 7.397

5.  Oxidative modification of low density lipoprotein (LDL) by activated human monocytes and the cell lines U937 and HL60.

Authors:  M K Cathcart; G M Chisolm; A K McNally; D W Morel
Journal:  In Vitro Cell Dev Biol       Date:  1988-10

6.  Immunity to Schistosoma mansoni in guinea-pigs vaccinated with radiation-attenuated cercariae. T-cell activation of macrophages for larval killing.

Authors:  J R Gordon; D J McLaren
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

7.  Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine.

Authors:  I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.